Molecular Biomarker Revolution in Metastatic NSCLC

During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. Participants will learn how to integrate next generation sequencing (NGS) into their biomarker testing workflows and optimize its use for patients. Finally, faculty share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients. This activity offers 1.0 CME/CMLE credit. Register for the online course here: store.ascp.org/productlisting.... Funded by an independent educational grant from AstraZeneca Pharmaceuticals.